Rallybio Corporation (NASDAQ: RLYB) announced a 1‑for‑8 reverse stock split of its common shares, effective 12:01 a.m. Eastern Time on February 6 2026. The split will consolidate eight existing shares into one, raising the per‑share price and reducing the total number of shares outstanding so the company can meet Nasdaq’s minimum $1.00 bid‑price requirement and avoid delisting from the Nasdaq Capital Market.
All outstanding shares will be affected by the split. Shareholders who would receive fractional shares will receive cash equal to the fair‑market value of those fractions. The company’s par value will remain unchanged at $0.0001 per share, and the split will not alter the company’s capital structure beyond the change in share count.
The reverse split follows a series of Nasdaq deficiency notices. Rallybio first received a warning on February 24 2025 after its stock traded below $1.00 for 30 consecutive business days. An initial compliance deadline of August 25 2025 was missed, after which Nasdaq approved a transfer to the Capital Market and granted an additional 180‑day extension, setting a second compliance date of February 23 2026. The February 6 split is the company’s last opportunity to raise its share price before that deadline.
Rallybio’s recent financial results provide context for the need for the split. In the third quarter of 2025 the company posted a net income of $16.0 million, or $0.36 per share, compared with a net loss of $11.5 million, or $0.26 per share, in the same period of 2024. Revenue fell to $0.2 million from $0.3 million year‑over‑year, but the company’s net income improved thanks to reduced research and development expenses, lower payroll costs from workforce reductions, and a one‑time gain from the sale of its REV102 program. CEO Stephen Uden emphasized disciplined execution, noting that the company “continued to execute with discipline and focus, advancing our lead program, RLYB116, and achieving a key clinical milestone.”
The reverse split preserves liquidity that Rallybio will need to pursue future financing and strategic partnerships. The company’s pipeline remains focused on rare‑disease therapeutics, with RLYB116—a C5 inhibitor—leading the portfolio, and RLYB332 in preclinical development. The discontinued RLYB212 program and ongoing workforce reductions have strained the company’s financial health, reflected in a Piotroski F‑Score of 3 and an Altman Z‑Score of –2.08. Maintaining Nasdaq listing is therefore critical for access to institutional investors and for the company’s ability to raise capital to support its pipeline and operations.
Investors reacted negatively to the announcement, reflecting concerns about the company’s financial distress and the need for a reverse split. The move is a regulatory safeguard rather than a positive catalyst, but it is a necessary step to keep Rallybio listed and to preserve the ability to raise capital in the future.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.